VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. This approach combines cutting-edge bioinformatics and proteomics with an in-depth understanding of key inflammatory processes to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies. Disease areas in which the company portfolio's technology may have utility include multiple sclerosis, lupus, rheumatoid diseases, diabetes, as well as a number of other important and clinically unmet indications. The company has already identified a number of highly pre-validated cellular targets and counter structures and is evaluating their therapeutic potential in relevant preclinical disease models.

The company was co-founded by Drs. Craig Smith and Steven Wiley. Dr. Smith and Dr. Ray Goodwin, a member of the VLST Scientific Advisory Board, were co-inventors of Enbrel; a biologic therapy for the treatment of multiple inflammatory disorders which has annual sales already exceeding $1.9 billion in 2004.

Portfolio Home